Pegylated tetanus neurotoxins and treatment of hypotonia
AssigneeSnoretox Pty Ltd
InventorsThomas McLean, Peter Smooker, Luke Norbury, Peter Coloe, Russell Conduit, Anthony Sasse
Life of this patent
Estimating the term…
Abstract
The invention relates to a composition comprising a first PEGylated tetanus neurotoxin (PEG-TeNT) comprising tetanus neurotoxin (TeNT) conjugated to polyethylene glycol (PEG) and a second TeNT. The invention also relates to various PEG-TeNTs. The invention also relates to a method of treating hypotonia using the composition or various PEG-TeNTs, and a kit comprising the composition or various PEG-TeNTs. In one embodiment, the hypotonia is obstructive sleep apnoea.
Claims8
A method of treating hypotonia in a mammalian subject having pre-existing anti-tetanus neurotoxin (TeNT) antibodies due to prior exposure to TeNT or due to pre-immunization with tetanus toxoid, the method comprising administering to said subject a therapeutically effective amount of:
- a first TeNT that is active and PEGylated (PEG-TeNT) comprising one or more surface serine-to-cysteine amino acid substitutions within the amino acid sequence of SEQ ID NO:
- 1, wherein the one or more substituted cysteines are conjugated to polyethylene glycol (PEG);
- and
- a second TeNT that is an inactive TeNT consisting of SEQ ID NO:
- 1 carrying the R1225E and W1288A inactivating mutations, wherein the second inactive TeNT is not PEGylated.
Dependencies are inferred from the claim text.